Results 131 to 140 of about 26,462 (230)

Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding

Acta Medica Indonesiana, 2019
Dual antiplatelet therapy (DAPT) is the mainstay of secondary prevention treatment for acute coronary syndrome (ACS) and ischemic stroke, especially after coronary intervention. DAPT consists of aspirin and P2Y12 receptor inhibitor (e.g.
Muhammad Begawan Bestari, Ignatius R Joewono   +1 more
doaj   +2 more sources

The DRY motif at work: the P2Y12 receptor case [PDF]

Journal of Thrombosis and Haemostasis, 2014
G. Rovati, V. Capra
openaire   +2 more sources

Unveiling the Molecular Mechanism of Intestinal Metabolite para‐Cresol in Modulating Neuroinflammation and Synaptic Dysfunction: Implications for Autism Spectrum Disorder

Journal of Neurochemistry, Volume 170, Issue 5, May 2026.
Here we investigated the effect of p‐Cresol on different brain‐cell types to speculate on their specific contribution to autism spectrum disorder (ASD) synaptic dysfunctions. Our in vitro data show that p‐Cresol impairs dendritic arborization and length, disrupts the excitatory/inhibitory balance, and induces glial activation and inflammatory responses.
Wenjie Liao, Kristy Antonioni, Federica Silvestri, Monica Piemontese, Martina Bodria, Eleonora Daini, Antonio M. Persico, Michele Zoli, Andreas M. Grabrucker, Antonietta Vilella   +9 more
wiley   +1 more source

Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation. [PDF]

Int J Mol Sci, 2023
Lofrumento F, Irrera N, Licordari R, Perfetti S, Nasso E, Liotta P, Isgrò G, Garcia-Ruiz V, Squadrito F, Carerj S, Di Bella G, Micari A, Costa F.   +12 more
europepmc   +1 more source

High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease

JCI Insight
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD).
Deirdre Nolfi-Donegan, Gowtham K. Annarapu, Claudette St. Croix, Michael Calderon, Cheryl A. Hillery, Sruti Shiva   +5 more
doaj   +1 more source

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists. [PDF]

Biomolecules, 2023
Hsin CH, Dingemanse J, Henrich A, Bernaud C, Gehin M, Krause A.   +5 more
europepmc   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4376-4381, May 2026.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source

Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI: Meta‐analysis

Clinical and Translational Science
Selection of rational antagonists of P2Y12 receptor for CAD patients who inherit CYP2C19 LoF alleles remains still conflicting. This study compared the clinical outcomes in CAD patients inheriting CYP2C19 LoF alleles undergoing PCI and treated with ...
Mohitosh Biswas, Murshadul Alam Murad, Maliheh Ershadian, Most Sumaiya Khatun Kali, Chonlaphat Sukasem   +4 more
doaj   +1 more source

Pharmacogenetics of P2Y₁₂ receptor inhibitors. [PDF]

Pharmacotherapy, 2023
Thomas CD, Williams AK, Lee CR, Cavallari LH.   +3 more
europepmc   +1 more source

Opioids and oral P2Y12 receptor inhibitors: A drug-drug interaction. [PDF]

Cardiol J, 2022
Kubica J.
europepmc   +1 more source